NAUT at a glance
Nautilus Biotechnology Inc (NAUT, SEC CIK 1808805) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on September 11, 2026 and Form 4 insider filings as recently as June 22, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- As of June 30, 2026, 20 institutional investment managers tracked by SignalX reported holding Nautilus Biotechnology Inc (NAUT) shares worth $20.8 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by AH Equity Partners Bio II, L.L.C. on June 2, 2026 of 4,615,974 shares at $2.35 per share.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Insiders · 90 days
- 0 buys · 0 sells
- No open-market trades
- 13F holders
- 20 funds
- $20.8M · +5 vs prior quarter
- Latest 10-Q
- Jul 28, 2026
- Quarterly report
SignalX for NAUT
Don't miss the next NAUT filing
- Alerts as it files. A push when NAUT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut NAUT, by share count.
- Ask anything. An AI agent that reads every NAUT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| NAZEM FARZAD | A | Jun 18, 2026 | 45,000 | - |
| Akinsanya Karen | A | Jun 18, 2026 | 45,000 | - |
| McIlwain Matthew S | A | Jun 18, 2026 | 45,000 | - |
| Epperly Melissa B, | A | Jun 18, 2026 | 45,000 | - |
| Posard Matthew L. | A | Jun 18, 2026 | 45,000 | - |
| AH Equity Partners Bio II, L.L.C. | Sell | Jun 2, 2026 | 4,615,974 | $2.35 |
| AH Equity Partners Bio II, L.L.C. | Sell | Jun 2, 2026 | 384,026 | $2.35 |
| Murphy Matthew B. | A | Mar 2, 2026 | 160,000 | - |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Net Income | -$63.7M | -$70.8M | -$59.0M | |
| Balance Sheet | ||||
| Total Assets | $305.6M | $242.7M | $191.1M | |
| Equity | $265.4M | $208.7M | $157.0M | |
| ROE | -24.0% | -33.9% | -37.6% | |
| Per Share | ||||
| EPS | $-0.51 | $-0.56 | $-0.47 | |
| Cash Flow | ||||
| Operating CF | -$51.7M | -$59.1M | -$50.7M | |
| CapEx | $2.4M | $2.1M | $1.3M | |
Source: XBRL data in Nautilus Biotechnology Inc (NAUT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q2 2026Aggregate NAUT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q2 2026 | 20 | $20.8M |
| Q1 2026 | 15 | $27.0M |
| Q4 2025 | 14 | $12.8M |
| Q3 2025 | 16 | $6.0M |
| Q2 2025 | 17 | $5.7M |
| Q1 2025 | 18 | $6.4M |
| Q4 2024 | 13 | $11.9M |
| Q3 2024 | 9 | $11.3M |
- BlackRock+2.50M (+1332%)
- Renaissance Technologies LLC+424.8K (+160%)
- State Street Corp+343.2K (+159%)
- Northern Trust+274.2K (+256%)
- Dimensional Fund Advisors+146.7K (+45%)
- Millennium Management−1.08M (-85%)
- Goldman Sachs Group−138.0K (-35%)
- Citadel Advisors LLC+1.90M
- JPMorgan Chase & Co+614.2K
- Vanguard Portfolio Management LLC+337.7K
- BNY Mellon+122.6K
- T. Rowe Price Group+40.8K
- Amazon.com Inc−1.46M
Source: 13F-HR filings on SEC EDGAR (aggregated from 122 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
NAUT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Sep 11, 2026 | - | - | - |
| 8-K | Jul 28, 2026 | - | - | - |
| 10-Q | Jul 28, 2026 | Jun 30, 2026 | - | |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 4 | Jun 22, 2026 | - | - | - |
| 8-K | Jun 18, 2026 | - | - | - |
| 4 | Jun 4, 2026 | - | - | |
| 8-K | Apr 28, 2026 | - | - | - |
| 10-Q | Apr 28, 2026 | Mar 31, 2026 | - | |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 4 | Mar 4, 2026 | - | - | - |
| 10-K | Feb 26, 2026 | Dec 31, 2025 | - | |
| 8-K | Feb 26, 2026 | - | Analysis | - |
| 10-Q | Oct 28, 2025 | Sep 30, 2025 | - | |
| 10-Q | Jul 31, 2025 | Jun 30, 2025 | - | |
| 10-Q | Apr 29, 2025 | Mar 31, 2025 | - | |
| 10-K | Feb 27, 2025 | Dec 31, 2024 | - | |
| 10-Q | Oct 29, 2024 | Sep 30, 2024 | - |
Related Health Care companies
- TXG · 10x Genomics, Inc.Laboratory Analytical Instruments
- A · Agilent TechnologiesLaboratory Analytical Instruments
- ALMR · Alamar Biosciences IncLaboratory Analytical Instruments
- AVTR · Avantor IncLaboratory Analytical Instruments
- BIO · Bio-rad Laboratories IncLaboratory Analytical Instruments
- BRKR · Bruker CorpLaboratory Analytical Instruments
- CTKB · Cytek Biosciences, Inc.Laboratory Analytical Instruments
- EYPT · EyePoint, Inc.Laboratory Analytical Instruments
NAUT SEC filings: frequently asked questions
Which institutions hold NAUT stock?
As of June 30, 2026, the largest Nautilus Biotechnology Inc (NAUT) holders among the 13F filers tracked by SignalX were BlackRock ($5.0 million), Vanguard Capital Management LLC ($4.8 million), Citadel Advisors LLC ($3.5 million), Renaissance Technologies LLC ($1.3 million), JPMorgan Chase & Co ($1.1 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What are the latest NAUT SEC filings?
Nautilus Biotechnology Inc (NAUT) filed its latest 10-K annual report on February 26, 2026, a 10-Q quarterly report on July 28, 2026, an 8-K current report on September 11, 2026 and a Form 4 insider filing on June 22, 2026.
What is NAUT's SEC CIK number?
Nautilus Biotechnology Inc (NAUT)'s SEC Central Index Key (CIK) is 1808805. EDGAR lists every NAUT filing under that number.
Ask anything about NAUT
The research agent reads NAUT's filings, financials, insider trades and 13F holders, then answers with sources.